NO983177L - Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer - Google Patents

Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Info

Publication number
NO983177L
NO983177L NO983177A NO983177A NO983177L NO 983177 L NO983177 L NO 983177L NO 983177 A NO983177 A NO 983177A NO 983177 A NO983177 A NO 983177A NO 983177 L NO983177 L NO 983177L
Authority
NO
Norway
Prior art keywords
preparation
centroman
enantiomer
prophylaxis
treatment
Prior art date
Application number
NO983177A
Other languages
Norwegian (no)
Inventor
Michael Shalmi
Ved Prakash Kamboj
Omkar Prasad Asthana
Suprabhat Ray
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO983177L publication Critical patent/NO983177L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse til- veiebringer en ny anvendelse av 1-enan-tiomeren av centkroman eller et farma- søytisk akseptabelt salt derav i kom- binasjon med en farmasøytisk akseptabel bærer til fremstilling av et farmasøytisk preparat for behandling eller pro- fylakse av brystkreft.The present invention provides a novel use of the 1-enantiomer of centroman or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier for the preparation of a pharmaceutical preparation for the treatment or prophylaxis of breast cancer.

NO983177A 1996-01-11 1998-07-10 Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer NO983177L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1000096P 1996-01-11 1996-01-11
DK77696 1996-07-11
PCT/DK1997/000007 WO1997025034A1 (en) 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Publications (1)

Publication Number Publication Date
NO983177L true NO983177L (en) 1998-07-10

Family

ID=26064631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983177A NO983177L (en) 1996-01-11 1998-07-10 Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Country Status (12)

Country Link
EP (1) EP0873119A1 (en)
JP (1) JP2001500101A (en)
KR (1) KR19990077157A (en)
AU (1) AU1367197A (en)
BR (1) BR9706966A (en)
CA (1) CA2241462A1 (en)
CZ (1) CZ217198A3 (en)
HU (1) HUP9901633A3 (en)
IL (1) IL124881A0 (en)
NO (1) NO983177L (en)
PL (1) PL328135A1 (en)
WO (1) WO1997025034A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024032A1 (en) * 1997-11-10 1999-05-20 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
AU2011253842B2 (en) * 1998-06-11 2014-08-14 Endorecherche Inc. Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
WO2006042409A1 (en) 2004-10-20 2006-04-27 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
JP5558358B2 (en) 2007-10-16 2014-07-23 レプロス セラピューティクス インコーポレイティド TRANS-clomiphene for metabolic syndrome
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
KR20130031339A (en) 2010-06-16 2013-03-28 앙도르쉐르슈 인코포레이티드 Methods of treating or preventing estrogen-related diseases
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
AU2016352592B2 (en) 2015-11-10 2023-04-27 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof

Also Published As

Publication number Publication date
JP2001500101A (en) 2001-01-09
WO1997025034A1 (en) 1997-07-17
AU1367197A (en) 1997-08-01
HUP9901633A2 (en) 1999-10-28
CA2241462A1 (en) 1997-07-17
BR9706966A (en) 1999-05-04
HUP9901633A3 (en) 2000-02-28
EP0873119A1 (en) 1998-10-28
KR19990077157A (en) 1999-10-25
CZ217198A3 (en) 1998-11-11
IL124881A0 (en) 1999-01-26
PL328135A1 (en) 1999-01-18

Similar Documents

Publication Publication Date Title
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
NO20012774D0 (en) Preparation and method using essential plant oils
ES2172654T3 (en) USE OF NSAID FOR THE TREATMENT OF SCALE CARCINOMAS OF THE ORAL OR OROPHARING CAVITY.
ATE234274T1 (en) DERIVATIVES OF ADAMANTAN
CY1108610T1 (en) IL-2 Peptides and their derivatives and their use as therapeutic agents
SE9704544D0 (en) Novel compounds
MX9703621A (en) Novel amino acid derivatives with improved multi-drug resistance activity.
BG103417A (en) Condensed pyrimidine bicyclic derivatives
DE69729786D1 (en) HIGHLY CONCENTRATED, LYOPHILIZED AND LIQUID FACTOR IX FORMULATIONS
SE9704546D0 (en) Novel compounds
ATE231872T1 (en) THIAZOLOPYRIMIDE DERIVATIVES
BG101118A (en) Therapeutical compounds
YU60900A (en) Novel crystalline forms of an antiviral benzimidazole compound
UA41355C2 (en) Agent for treating neuro-aids
IL118269A0 (en) Tetralin derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
NO173998C (en) Analogous Procedures for Preparing Therapeutically Active Benzimidazole Derivatives
NO983177L (en) Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
ES2173858T3 (en) ANALOGS OF HUPERZINA A.
SE9802208D0 (en) Novel compounds
SE9802937D0 (en) Novel compounds
EA200000242A1 (en) FANHINONA APPLICATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ES2135722T3 (en) 1,5-BENZODIACEPINES 5-HETEROCICLICAS MODULADORAS DE LA CCK OR DEL GASTRINA.
SE9802209D0 (en) Novel compounds
IT9020020A0 (en) "2-SUBSTITUTED N,N'-DITRIMETHOXYBENZOILPIPERAZINES, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353